CUPISCO

A Phase II, Active-Controlled, Multicenter Study Comparing The Efficacy & Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling vs. Platinum Based Chemotherapy in Patients with Cancer of Unknown Primary Site who Have Received Three Cycles of Platinum Doublet Chemotherapy, MX39795 (CUPISCO)

II

interventionell

International

Carboplatin/Paclitaxel oder Cisplatin/Gemcitabin

Status: In Rekrutierung

Zeitraum

2018

2021

Zentren

134

134

Keine Zentren gesucht

Patienten

790

480

19.04.2022

Klinische Settings

1st line

Beteiligte

AIO-Arbeitsgruppen

Sponsor

Hoffmann-La Roche

Kooperierende Fachgesellschaft(en)

Foundation Medicine, Inc.

Identifier

AIO-CUP-0117/ass

2017-003040-20

MX39795

Kontakt

Leitung

Prof. Dr. med. Alwin Krämer

Ansprechpartner*in

Prof. Dr. med. Alwin Krämer
Telefon +49-6221 421440